Vascular Graft Bridged En Bloc Resection for Biliopancreatic Cancer Invading the Portal System

Yun-Gang Lai¹², Yue Gao³, Jun-Gui Liu¹, Wei Lyu¹, Hong Sun⁴, Di Cheng¹, Shuo Yang¹, Ji-Xiang Liu², Wei-Hong Duan¹

¹Department of Hepatobiliary Surgery, PLA Rocket Force General Hospital, Beijing 100088, China
²Department of General Surgery, The First Hospital of Handan, Handan, Hebei 056002, China
³Department of Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
⁴School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

To meet the requirement of extensive resection of pancreatic cancer with portal or mesenteric venous invasion, the innovation of Vascular Graft Bridged En Bloc Resection (VGBEBR) has been adopted to treat advanced biliopancreatic cancer in the Department of Hepatobiliary Surgery of the PLA Rocket Force General Hospital since 2013. This attempt could not only broaden surgical indications of radical resection and lymphadenectomy but also increase R0 resection rate, especially for the case with severe invasion in the portal and mesenteric venous system.[1]

Thirteen patients (five males and eight females; age: 28–70 years) received “VGBEBR” from December 2013 to January 2015. All patients were diagnosed with locally advanced biliopancreatic cancer without systemic metastases confirmed by computed tomography and magnetic resonance imaging, and vascular grafts 8 mm long were prepared preoperatively. The extent of the invasion abutting or invading to the portal vein (PV) was >5 cm, which was unavailable to end-to-end anastomoses; thus, the following efforts were attempted: (1) The gallbladder was removed and the hepatoduodenal ligament was dissected to expose the PV measuring approximately 3 cm. (2) The 2-cm trunk section of the superior mesenteric vein (SMV) was anatomized for the anastomoses after the exposure, rather than the branches far down. (3) Vascular graft 40 cm long was used to perform the end-to-end anastomoses between the PV and SMV, followed by the ligation and transaction of PV and SMV 0.5 cm below and above the anastomoses, respectively, with the purpose of obstructing the PV and preventing the intrahepatic metastases caused by extrusion of tumors. PV obstruction should be controlled within 30 min. (4) The 40-cm graft was drawn to make space for the following manipulations in the surgical field. Whether to perform total pancreatectomy (TP) or head resection was determined by the location of the tumors. In case of the hepatic artery (HA) invasion, the reconstruction was needed after the removal of the tumors. The overlong graft had better be shortened to 10–12 cm. (5) After the anastomoses, the reconstructions were accomplished in turn, with pancreatic, biliary, and gastrointestinal procedures.

All the cases were successfully completed and no operative mortality occurred. All the cases were diagnosed as Stage III according to the modified UICC-3 TNM classification[2] and were performed with R0 resection, except for one with R1 resection. The R0 rate was remarkably promoted to 92.3% (12/13). The intraoperative results and the postoperative pathology are shown in Supplementary Table 1. The complications included postoperative bleeding in three patients and gastrointestinal obstruction and anastomotic and lymphatic fistula in three patients, and the complication rate was 46.2%. Death happened in two cases (survived more than 300 days): one related to hemorrhage (day 4) and the other due to uncontrolled diarrhea secondary to electrolyte imbalance. The overall survival rate was 84.6%.

Access this article online

Quick Response Code:

Website: www.cmj.org

DOI: 10.4103/0366-6999.213977

Address for correspondence: Dr. Wei-Hong Duan, Surgical Center for Hepatobiliary Diseases, Rocket Force General Hospital of the People’s Liberation Army, Beijing 100088, China
E-Mail: changxinzhang@163.com

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com
© 2017 Chinese Medical Journal | Produced by Wolters Kluwer - Medknow

Received: 06-06-2017 Edited by: Xin Chen
How to cite this article: Lai YG, Gao Y, Liu JG, Lyu W, Sun H, Cheng D, Yang S, Liu JX, Duan WH. Vascular Graft Bridged En Bloc Resection for Biliopancreatic Cancer Invading the Portal System. Chin Med J 2017;130:2259-60.
The main indications for this surgery were as follows: (1) presented with the PV invasion and the gap between the pancreas and the PV disappeared; (2) the range of the invasion was usually >5 cm and unavailable to the direct end-to-end anastomoses; (3) the invasion was severe, expanding to the whole pancreas; (4) shallow and moderate invasion occurred in the HA; (5) the PV invasion resulted in regional portal hypertension. TP was performed in nine patients, and this procedure was determined by the following aspects: (1) Pancreatic cancer was mostly located in the neck and body, which was prone to the development to the head and tail. The procedure of TP should not be abandoned concerning its potentials in the achievements of negative margin and R0 resection.\(^{[3,4]}\) (2) In terms of postoperative complications, pancreatic fistula should be given more concern.

For this approach, there are four highlights, namely B-NET: B stands for the bridge; N means no touch; E represents en bloc resection; and T signifies the TP. Postoperatively, complications only occurred in three patients and were cured after conservative treatment. In view of these surgical benefits, we are convinced that this approach is safe and feasible and worth attempting. Although the long-term survival rate has not been confirmed yet, it is worthwhile to explore further to maximize its potentials in the improvement of the survival rate for the advanced pancreatic cancer.

Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.

Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. The patients understand that their names and initials will not be published in the journal and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
This study was supported by a grant from the Capital Clinical Foundation of China (No. Z161100000516170).

Conflicts of interest
There are no conflicts of interest.

References
1. van Heek NT, van Geenen RC, Busch OR, Gouma DJ. Palliative treatment in “peri”-pancreatic carcinoma: Stenting or surgical therapy? Acta Gastroenterol Belg 2002;65:171-5.
2. Hirata K, Egawa S, Kimura Y, Nobuoka T, Oshima H, Katsuramaki T, et al. Current status of surgery for pancreatic cancer. Dig Surg 2007;24:137-47. doi: 10.1159/000102067.
3. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141:610-8. doi: 10.1016/j.surq.2006.12.013.
4. Satoi S, Murakami Y, Motoi F, Sho M, Matsumoto I, Uemura K, et al. Reappraisal of total pancreatectomy in 45 patients with pancreatic ductal adenocarcinoma in the modern era using matched-pairs analysis: Multicenter Study Group of Pancreatobiliary Surgery in Japan. Pancreas 2016;45:1003-9. doi: 10.1097/MPA.0000000000000579.
### Supplementary Table 1: Intraoperative results and the postoperative pathology of 13 patients with biliopancreatic cancer

| Patient number | Scope of resection                                                                 | OR bleeding (ml) | Duration of operation (h) | Artery reconstruction | Surgical margin | Pathology                                                                 | TNM staging |
|----------------|-----------------------------------------------------------------------------------|------------------|---------------------------|-----------------------|----------------|---------------------------------------------------------------------------|--------------|
| 1              | Whole pancreas, duodenum, spleen, segmental PV, SMV, and HA                        | 4000             | 7.5                       | HA reconstruction     | R1 negative     | Pancreatic poorly/ moderately differentiated adenocarcinoma               | T4N1M0       |
| 2              | Pancreatic head, duodenum, gallbladder, distal CBD, distal stomach, proximal jejunum, segmental SMV | 1600             | 9.0                       | No                    | R0 negative     | Pleomorphic leiomyosarcoma                                                | TXN1M1       |
| 3              | Pancreatic head, duodenum, gallbladder, distal CBD, distal stomach, proximal jejunum, segmental SMV | 6000             | 9.0                       | No                    | R0 negative     | Duodenum poorly/ moderately differentiated adenocarcinoma                | T3N1M0       |
| 4              | Hepatic right trilobectomy, distal CBD, distal stomach, pancreatic head, duodenum, proximal jejunum, segmental SMV | 8000             | 11.0                      | No                    | R0 negative     | Cholecyst poorly/ moderately differentiated adenocarcinoma                | T3N1M0       |
| 5              | Whole pancreas, duodenum, spleen, segmental PV, SMV, distal CBD, proximal jejunum | 3100             | 11.0                      | No                    | R0 negative     | Pancreas well-differentiated papillary squamous cell carcinoma            | T3N0M0       |
| 6              | Whole pancreas, duodenum, spleen, segmental PV, SMV, distal stomach, distal CBD, proximal jejunum | 4000             | 10.5                      | No                    | R0 negative     | Pancreatic acinar adenocarcinoma                                          | T3N1M0       |
| 7              | Whole pancreas, duodenum, spleen, segmental PV, SMV, distal CBD, proximal jejunum | 4000             | 7.5                       | No                    | R0 negative     | Pancreas moderately differentiated adenocarcinoma                         | T3N1M0       |
| 8              | Whole pancreas, duodenum, spleen, segmental PV, SMV, distal stomach, distal CBD, proximal jejunum | 800              | 5.5                       | No                    | R0 negative     | Pancreatic moderately differentiated adenocarcinoma                       | T3N1M0       |
| 9              | Whole pancreas, duodenum, spleen, segmental PV, SMV, distal stomach, distal CBD, proximal jejunum | 350              | 7.0                       | No                    | R0 negative     | Pancreatic moderately/poorly differentiated adenocarcinoma               | T3N1M0       |
| 10             | Whole pancreas, duodenum, spleen, segmental PV, SMV, distal stomach, distal CBD, proximal jejunum | 2000             | 8.0                       | No                    | R0 negative     | Pancreatic moderately/poorly differentiated adenocarcinoma               | T3N1M0       |
| 11             | Whole pancreas, duodenum, spleen, segmental PV, SMV, distal stomach, distal CBD, proximal jejunum | 380              | 6.5                       | No                    | R0 negative     | Pancreatic moderately/poorly differentiated adenocarcinoma               | T3N1M0       |
| 12             | Whole pancreas, duodenum, spleen, segmental PV, SMV, distal stomach, distal CBD, proximal jejunum | 3500             | 7.0                       | No                    | R0 negative     | Pancreatic highly/ moderately differentiated adenocarcinoma              | T3N0M0       |

*Contd...*
**Supplementary Table 1: Contd...**

| Patient number | Scope of resection                                                                 | OR bleeding (ml) | Duration of operation (h) | Artery reconstruction | Surgical margin | Pathology                                          | TNM staging         |
|----------------|-----------------------------------------------------------------------------------|------------------|---------------------------|-----------------------|----------------|----------------------------------------------------|---------------------|
| 13             | Pancreatic head, duodenum, spleen, segmental PV, SMV, distal stomach, distal CBD, proximal jejunum | 1000             | 7.5                       | No                    | R0 negative    | Pancreatic moderately differentiated adenocarcinoma | T3N0M1              |

*Serous cystic adenoma is generally defined as pathological “benign,” but its biological behavior is very invasive, and such disease was clinically treated under malignant protocol. CBD: Common bile duct; PV: Portal vein; SMV: Superior mesenteric vein; HA: Hepatic artery; OR: Operation; TNM: Tumor, node, metastasis.*